
|Articles|March 2, 2002
Alefacept valuable against psoriatic arthritis
New Orleans - Results from a single-center pilot study indicatethat I.V. alefacept (Amevive), the human LFA3-IgG1 fusion protein, may safelyand effectively improve the skin and joint manifestations of psoriatic arthritis,researchers from the Academic Medical Center, University of Amsterdam, TheNetherlands, reported at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















